Professor Steve Bain
Swansea University, Swansea (United Kingdom of Great Britain & Northern Ireland)
Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme
Event: ESC Congress 2018
Topic: Antidiabetic Pharmacotherapy
Session: Cardiac patients with comorbidities
Reduction in systolic blood pressure with semaglutide treatment is not due to weight loss alone: data from SUSTAIN 1-5
Event: ESC Congress 2018
Topic: Antidiabetic Pharmacotherapy
Session: Cardiovascular risk and its modification
Connect with the speakers: questions & answers.
Event: ESC Congress 2018
Topic: Diabetes and the Heart
Session: Joining clinical practices: cardiovascular disease and type 2 diabetes
Linking the dots: cardiovascular disease, type 2 diabetes and other comorbidities.
Event: ESC Congress 2018
Topic: Diabetes and the Heart
Session: Joining clinical practices: cardiovascular disease and type 2 diabetes
ESC 365 is supported by
